Morphosis Capital’s Post

🤝 Since 2021, when we established our partnership with Cronos Med, we have believed in the company’s reputation and potential and continuously supported Cronos Med in consolidating its position as the undisputed leader in aesthetic and plastic medicine in Romania. How did Morphosis Capital contribute to Cronos Med’s development? In the words of Constantin Stan MD PhD, founder of Cronos Med: “I traveled, visited clinics, and met the doctors who built them. Some of my colleagues followed a similar trajectory, establishing businesses and constructing clinics. Following this, they went to investment funds not only for financial support, but also for their expertise in carefully managing funds, generating revenue, and fostering the growth of their businesses - ensuring optimal performance.” #Morphosis #CronosMed #PrivateEquity #entrepreneurship

The Department of Industry, Science and Resources (DISR) has released another case study featuring PolyActiva, highlighting what can be achieved with support and investment into venture capital companies throughout the venture capital stages. ▶️ https://lnkd.in/g4kZHGnb PolyActiva is impressively pioneering an ocular implant for sustained drug delivery to the eye, which can deliver medication directly to affected tissue. If successful, this could be ground-breaking for glaucoma patients, many of whom are elderly and suffer sever impacts including blindness when forgetting to take medication or applying incorrect doses of it. PolyActiva’s ocular implant is inserted directly into the eye and the technology enables medication to be released as needed to the targeted area. The support and investment PolyActiva has received from Brandon Capital through the Australian Government's Biomedical Translation Fund, has enabled them to conduct the research and clinical trials to nurture innovation into commercially successful companies.   DISR is a partner of Innovation Bay’s VC community, Aurora, and is committed to fostering venture capital investment in startups. Explore some of the Australian Government’s diverse range of programs, including: 👉 Venture Capital Limited Partnerships https://bit.ly/3wzgo3r 👉 Early-Stage Venture Capital Limited Partnerships https://bit.ly/48vsHLu 👉 Australian Funds of Funds https://bit.ly/4bTK1wH 👉 Biomedical Translation Fund https://bit.ly/3uRZVa4 👉 Pooled Development Funds https://bit.ly/49AkPJR   These programs serve as catalysts for growth, facilitating globally competitive businesses. Noteworthy is the substantial impact of DISR's tax concession programs, attracting both foreign and local capital into the Australian venture capital sector. Since the inception of these initiatives, an impressive $30 billion in capital has been committed, benefiting approximately 2,500 early-stage businesses in scaling their ventures.   For those in the VC realm, we invite you to visit DISR's website to discover how their programs can elevate your investment strategies: https://bit.ly/3OjbMof https://bit.ly/3UlQUAE #DISR #VC #venturecapital #innovationbay #partner #departmentofindustryscienceresources #aurora #casestudy #business.gov.au #departmentofhealthandagedcare

Update on secondary transactions - glad to be featured in an interview with the German Private Equity and Venture Capital Association (BVK Bundesverband Beteiligungskapital) on current trends and developments in secondary transactions, many thanks Anna Jacobi and team. #Funds #PrivateEquity #Secondaries #GPLed #LPLed

📢 Attention Investors & Followers of Cytta Corp! 🌟 Join us for a Live Investor Business Update with our CEO, Gary Campbell, this Friday, May 10th, 2024 at 12 PM ET. Don't miss out on this opportunity to hear directly from leadership about the latest developments and future directions of Cytta Corp. 🔹 Event Details: Date: Friday, May 10th, 2024 Time: 12 PM Eastern Time Location: Live online – access details to follow Register here: https://loom.ly/0mnM4fY Gary will be discussing key business updates, recent milestones, and what's next for Cytta as we continue to innovate and lead in the technology solutions sector. Whether you're a current investor or considering investment, this update is crucial for understanding the exciting trajectory of our company. 👉 Save your spot now! Stay tuned for access details and make sure to mark your calendar. You won’t want to miss the insights and forward-looking statements that will shape the future of our industry. 💬 Have questions for Gary? Submit them before the webinar to ensure they get addressed during the session. 🔗 Follow us for updates and visit Cytta.com for more information about our groundbreaking products and services. #CyttaCorp #InvestorUpdate #BusinessUpdate #LiveWebinar #TechnologyInnovation #GaryCampbell #InvestInInnovation

🧩 Human fit goes beyond traditional metrics and financial analyses; it is about understanding the people behind the businesses we invest in. This insightful perspective, presented by Gabriela Dumitru, Partner of Morphosis Capital, is embedded in our investment philosophy. We place significant emphasis on aligning with the founders and on finding a common vision and ambition for the business. As we venture into our second fund, we are unwavering in our commitment to human fit. By forging strong relationships based on trust and shared values, we create an environment where innovation flourishes, and companies can achieve their full potential. #Morphosis #humanfit #investment #PrivateEquity

EMERGING TECHNOLOGIES TO TACKLE CANCER 🩺 Discover how Grey Wolf Therapeutics uses cutting-edge technology targeting enzymes to tackle a wide range of diseases including cancer, while understanding how Resilience harnesses the power of digital solutions to improve remote patient monitoring for cancer patients. 📁 In this edition of our bi-monthly newsletter, we also review the acquisition of Reveal-Onna by Reveal, a merger that will result in cost and time saving procedures for professional teams. 👕 Beyond that, you will discover more about Sweden-based Syre and its endeavour to decarbonize and dewaste the second most polluting industry in the world: the fashion industry. 💸 Finally, we dive deeper into the launch of ETF Partners' fourth fund, a EUR 285 Mln fund dedicated to impact investing. Read the full newsletter ➡ https://lnkd.in/dbVUbe-b Lee el artículo completo ➡ https://lnkd.in/d8iUp78D #healthcare #innovation #impact

Is It Time to Take a Closer Look at GoHealth (GOCO)? According to Sidoti & Company, LLC Analyst Jim Sidoti: ‘Think Recent Pullback Is Overdone; Expect Improved Results By 4Q:24 With Improved Enrollment Systems; Maintain $18 Price Target GoHealth shares have been down 35% compared to a 6% increase in the Russell 2000 index since reporting lower-than-expected 2Q:24 results. We expect revenue to rebound 12% year over year in 4Q:24, with increased consumer switching due to rate increases and plan changes and as several midsized brokers exit the market. The company continues to develop technology to establish long-term customer relationships, improve customer service and cash flow, and reduce seasonality and maintained 2024 guidance for revenue to remain about flat and for operating margins to improve.’

Mark your calendar for this important B2B growth planning webinar.

🌟 Exciting news! After 15 months working with ILC Therapeutics as their fractional CFO, I’m thrilled to share that our recent fundraising round has been a success, and the cherry on top, my journey with the company continues 🚀. This round is a major milestone, helping us advance our two lead assets Alfacyte™ & Dermacyte™ towards clinic and hit key value inflection points for the business. 🎯 For those not in biotech, the closing of a fundraising round isn’t the time to slow down—it’s time to accelerate! 💥 and that's exactly what we are doing! I do have a sliver of capacity left (1-4 days/month) for fractional CFO work. If you or someone you know needs support, drop me a message! 📩 #FractionalCFO #FundraisingSuccess #Biotech #ClinicalTrials #Startups #CFO #BusinessGrowth #BiotechStartups #Leadership #Finance #Fundraising

At Sciety, our goal is to help our portfolio companies reach their full potential. We are here to support their growth, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. To learn more about what a partnership with Sciety can be like, read our recent interview with Christopher Aulin, CEO of our portfolio company Capitainer. Take a look at how Capitainer strengthened their market position, achieved a fully subscribed share issue in just two days, and expanded strategically into the US market – through a strategic collaboration with Sciety. Read the full story here: https://lnkd.in/dDiA2s9F #Sciety #Capitainer #VentureCapital